Adicet Bio (ACET) investor relations material

Pipeline and platform overview

• Leading development of gamma delta CAR-T cell therapy, an off-the-shelf platform with a favorable safety profile compared to alpha beta T cells.

• Lead program targets autoimmune diseases, with a significant clinical data update expected this month.

• Second program in prostate cancer is set to enter the clinic in Q4.

• In vivo CAR-T pipeline expected to reach the clinic in the second half of next year.

• Multiple milestones anticipated over the next 18 months, including data in SLE, lupus nephritis, and systemic sclerosis.

Differentiation and safety profile

• Gamma delta CAR-T offers outpatient administration, rapid availability, and avoids major safety issues seen with alpha beta T cells, such as ICANS and ICHS.

• Favorable safety profile has enabled FDA agreement for outpatient use in LN and SLE.

• No observed ICANS, no CRS beyond grade 2, and no need for chronic immunosuppression.

• Comparable efficacy to autologous CAR-T, with complete CD19 B-cell depletion and immune reset.

Competitive landscape and efficacy benchmarks

• Largest cell therapy dataset in LN and SLE to be shared, surpassing Novartis and BMS, whose programs are on hold due to safety.

• Efficacy rates for autologous CAR-T and obinutuzumab hover around 40-43% CRR, but require chronic immunosuppression and have higher infection rates.

• Off-the-shelf gamma delta CAR-T aims for immunosuppressant-free, one-time therapy with similar or better efficacy.